Phase 4Recruiting
Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (DATE-AGING)
Efficacy and Safety of Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients: A Prospective, Multicenter, Randomized Controlled Study
- Sponsor
- Southwest Hospital, China (Academic or other)
- Enrolment
- 798 planned
- Conditions
- Acute Ischemic Stroke Patients
- Interventions
- low-dose tenecteplase intravenous thrombolysis; standard-dose tenecteplase intravenous thrombolysis
- Ages
- older adults
- Registry
- NCT07294209
Full record on ClinicalTrials.gov
From the registry
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
Primary outcomes
- Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
History
Primary completion expected
Last registry update
Registered
Started